Genprex (GNPX) Stock Price, News & Analysis

Company Overview

Genprex, Inc. is a clinical-stage gene therapy company focused on developing novel treatments for cancer and diabetes by leveraging its proprietary delivery platforms. Headquartered in Austin, Texas, the company is advancing multiple programs designed to address underlying causes of disease through targeted gene transfer. Genprex’s technology seeks to restore normal cellular function by introducing therapeutic genes directly to affected tissues, offering a differentiated approach compared to conventional small molecule and biologic therapies.

The company’s lead oncology program, Oncoprex immunogene therapy, delivers a tumor suppressor gene to cancer cells with the goal of enhancing the body’s immune response and sensitizing tumors to established treatments. In parallel, Genprex is advancing GemRIS, a depot-based hydrogel system engineered to provide sustained local delivery of therapeutic genes for diabetic peripheral neuropathy. Together, these platforms demonstrate the company’s commitment to platform diversification and address sizable unmet medical needs.

Since its founding, Genprex has established collaborations with leading academic and medical research institutions to support preclinical and clinical development efforts. The company’s programs have progressed through early clinical studies, and Genprex continues to engage with regulatory agencies and key opinion leaders to shape its development pathways. Manufacturing partnerships and in-house capabilities support scalable production of viral vectors and hydrogels under current good manufacturing practices.

Under the leadership of President and Chief Executive Officer James A. Christofferson and Executive Chairman Kenneth Mirkin, Genprex is focused on advancing its pipeline through clinical milestones and strategic partnerships. The management team combines industry veterans in gene therapy, clinical development, and commercial strategy, positioning the company to potentially bring its first therapies to patients in need. Genprex’s efforts reflect a vision of harnessing the power of gene-based medicine to transform treatment paradigms in oncology and metabolic diseases.

Key Stats

• Today's Range: $0.28 to $0.29
• 50-Day Range: $0.22 to $0.36
• 52-Week Range: $0.20 to $3.97
• Volume: 532,157 shs
• Average Volume: 4.15 million shs
• Market Capitalization: $9.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genprex Stock Analysis - MarketRank™

Genprex scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genprex.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Genprex are expected to grow in the coming year, from ($5.70) to ($2.71) per share.

Price to Book Value per Share Ratio

Genprex has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.15% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently decreased by 7.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genprex does not currently pay a dividend.

Dividend Growth

Genprex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

8.15% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently decreased by 7.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genprex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.47% of the stock of Genprex is held by insiders.

Percentage Held by Institutions

Only 14.05% of the stock of Genprex is held by institutions.

GNPX Stock Analysis - Frequently Asked Questions

How have GNPX shares performed this year?

Genprex's stock was trading at $0.8516 at the beginning of the year. Since then, GNPX shares have decreased by 66.3% and is now trading at $0.2870.

How were Genprex's earnings last quarter?

Genprex (NASDAQ:GNPX) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.56.

When did Genprex's stock split?

Genprex's stock reverse split before market open on Friday, February 2nd 2024.The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genprex investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNPX
• CIK: 1595248
• Web: www.genprex.com
• Phone: (877) 774-4679
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.11 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -664.65%
• Return on Assets: -370.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.94
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 1.89

Miscellaneous

• Outstanding Shares: 33,145,000
• Free Float: 30,338,000
• Market Cap: $9.38 million
• Optionable: No Data
• Beta: -0.50